James A. Boiani, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Law360, in “Life Sciences Legislation and Regulation to Watch in 2017,” by John Kennedy. (Read the full version – subscription required.)
Following is an excerpt:
“[Clinical] trials can give you good data in some cases but can be real impediments to bringing a product to market,” said James A. Boiani of Epstein Becker Green. “Now with the cloud and web-based computing, there’s just a lot more information out there.”